These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19344431)

  • 1. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
    Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
    Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.
    Cai J; Terasaki PI; Bloom DD; Torrealba JR; Friedl A; Sollinger HW; Knechtle SJ
    Transplantation; 2004 Sep; 78(6):919-24. PubMed ID: 15385814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.
    Shapiro R; Zeevi A; Basu A; Tan HP; Kayler LK; Blisard DM; Thai NL; Girnita AL; Randhawa PS; Gray EA; Marcos A; Starzl TE
    Transplantation; 2008 Apr; 85(8):1125-32. PubMed ID: 18431232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.
    Shapiro R; Ellis D; Tan HP; Moritz ML; Basu A; Vats AN; Kayler LK; Erkan E; McFeaters CG; James G; Grosso MJ; Zeevi A; Gray EA; Marcos A; Starzl TE
    Am J Transplant; 2007 Dec; 7(12):2736-8. PubMed ID: 17908272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.
    Villanueva ME; Muñoz AS; Casasola CC; Africa JB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2222-5. PubMed ID: 18790198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.
    Tan HP; Donaldson J; Basu A; Unruh M; Randhawa P; Sharma V; Morgan C; McCauley J; Wu C; Shah N; Zeevi A; Shapiro R
    Am J Transplant; 2009 Feb; 9(2):355-66. PubMed ID: 19120078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.
    Tan HP; Donaldson J; Ellis D; Moritz ML; Basu A; Morgan C; Vats AN; Erkan E; Shapiro R
    Transplantation; 2008 Dec; 86(12):1725-31. PubMed ID: 19104412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Kupin W; Rosen A; Cordovilla T; Tueros L; Herrada E; Miller J
    Clin Transplant; 2008; 22(2):200-10. PubMed ID: 18339140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.
    Tan HP; Kaczorowski DJ; Basu A; Unruh M; McCauley J; Wu C; Donaldson J; Dvorchik I; Kayler L; Marcos A; Randhawa P; Smetanka C; Starzl TE; Shapiro R
    Am J Transplant; 2006 Oct; 6(10):2409-17. PubMed ID: 16889606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.
    Margreiter R; Klempnauer J; Neuhaus P; Muehlbacher F; Boesmueller C; Calne RY
    Am J Transplant; 2008 Jul; 8(7):1480-5. PubMed ID: 18510632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).
    Kirk AD; Hale DA; Mannon RB; Kleiner DE; Hoffmann SC; Kampen RL; Cendales LK; Tadaki DK; Harlan DM; Swanson SJ
    Transplantation; 2003 Jul; 76(1):120-9. PubMed ID: 12865797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection.
    Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M
    Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous islet and kidney transplantation in seven patients with type 1 diabetes and end-stage renal disease using a glucocorticoid-free immunosuppressive regimen with alemtuzumab induction.
    Tan J; Yang S; Cai J; Guo J; Huang L; Wu Z; Chen J; Liao L
    Diabetes; 2008 Oct; 57(10):2666-71. PubMed ID: 18633105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results.
    Kaufman DB; Leventhal JR; Gallon LG; Parker MA
    Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.